Investor Presentation
60
Investor presentation First six months of 2022
Novo NordiskⓇ
Large opportunity for activating more people with obesity to
seek treatment and increasing the number of prescribers
ONCE-WEEKLY
wegovy®
semaglutide injection 2.4 mg
75%
WegovyⓇ patient characteristics in the US
38%
81%
38.8
of patients new to anti-
obesity medication¹
of patients are female
Average BMI
of patients have ≥3 co-
morbidities
Of the people with overweight or obesity in the US, almost 90% have a weight-related comorbidity
BMI
140
(million of people)
27-30 30-35 35-40
(43) (52)
≥40
(25) (20)
Total
(140)
No obesity-related comorbidity²
7
6
2
2
17
million people with a
BMI > 27
Any obesity-related comorbidity
Hereof metabolic syndrome³
36
46
23
18
123
21
26
14
12
72
1 Patients new to anti-obesity medication reflect source of business, where 75% of patients starting WegovyⓇ are naïve to anti-obesity medication treatment and 25% have either switched from or restarted anti-obesity treatment, IQVIA Feb. 2022;
2 Individuals without any of the following obesity related conditions: T2DM, Pre-diabetes, NASH, NAFLD, obstructive sleep apnea, osteoarthritis, PCOS, ASCVD, Heart failure, asthma, urinary incontinence, hypertension, chronic kidney disease stg. 3 or 4,
musculoskeletal pain, dyslipideamia, metabolic syndrome; 3 Metabolic syndrome defined as two or more of dyslipidaemia; hypertension; prediabetes OR type II diabetes
Source: Novo Nordisk real world research; National Health And Examination Survey (NHANES) cycles 2015-2016 and 2017-2018View entire presentation